Arranta is more than a CDMO; we are a strategic partner, teaming up with innovators, aligning ourselves with their vision to unlock the potential of the microbiome, and bringing their therapies from lab to market. We support early clinical supply through to commercial manufacturing with an unparalleled commitment to build and operate the capacity needed to support this sector.  

Whether you are just starting out or encountering challenges unlocking the potential of your product, Arranta has the scientific expertise to bring your LBP products to life.

• Aerobes, obligate and facultative anaerobes, and spore formers
• Single-strain products, consortium, and genetically modified organisms
• actALIVE^TM Fast-to-Clinic Program
• ALIVE Biotherapeutic Products^TM manufacturing platform

Arranta is your partner for every step of the journey, whether your company is new to the sector, been a pioneer for some time, or a large biopharma company with an interest in the potential of the microbiome to improve healthcare.

• Analytical Development, Qualification, and Validation
• Fermentation and Lyophilization Development
• Drug Product Formulation and Process Development
• Process Characterization and Performance Qualification
• Pre-clinical, Clinical, and Commercial Manufacturing
  • Cell Banks
  • GMP Drug Substance
  • GMP Drug Product

Our capacity has been built specifically for LBP Manufacturing…and it’s available now.

• Anaerobic processing from thaw through drug product
• Low humidity processing from drying through packaging
• Purpose-built facilities for LBP (BSL1/BSL2) cGMP Manufacturing in compliance with:
  • FDA Code of Federal Regulations (Part 21)
  • ICH Guidelines

We understand it’s about more than just having capacity. Our team members are Arranta’s greatest strength.

Quality is at the center of everything we do.

• Robust phase-appropriate Quality Management System in place
• Best-in-class Quality IT Systems in place
• We offer regulatory support to help you submit your products for licensure and to take them through the regulatory path to approval.